Gary Amseian
Papers
1
Total Citations
2
H-Index
1
About
Dr. Gary Amseian is a urologic oncologist whose research centers on improving the detection and management of prostate cancer, with a particular focus on post-surgical monitoring and liquid biopsy technologies. His most notable contribution is the investigation of circulating free DNA (cfDNA) as a biomarker in patients with rising PSA levels after radical prostatectomy. In his 2024 study, Dr. Amseian demonstrated that cfDNA levels can serve as a non-invasive "liquid biopsy" to predict disease recurrence more accurately than traditional clinicopathological parameters alone. This work addresses a critical gap in prostate cancer care, where standard tools often fail to identify which patients will progress. While his research is still emerging, with his key paper accumulating 2 citations, the clinical relevance of his findings positions him as a promising voice in precision oncology. Dr. Amseian’s work is particularly valuable for students and clinicians seeking to understand how molecular biomarkers can refine risk stratification and guide treatment decisions in post-prostatectomy patients, ultimately moving toward more personalized cancer surveillance.
Research Focus
Key Achievements
Top Papers
- 1